CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Active, not recruiting
New York Medical College
CD34+ stem cell selection in children, adolescents and young adults receiving partially
matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral
blood stem cell transplant will be safe and well tolerated and be associated with a low
incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Active, not recruiting
Thomas Stauffer Larsen
The purpose of the study is to compare the efficacy and toxicity including quality of life
of two types of low-dose interferon alpha compounds (PegIntron and Pegasys) with hydroxyurea
(Hydrea), and to investigate the occurence of neutralizing antibodies against recombinant
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
New conditioning regimens are still needed to maximize efficacy and limit treatment-related
deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past
several years, the investigators have evaluated several new conditioning regimens that
incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has
synergistic activity with alkylating agents. Recent data have suggested that fludarabine may
be used in combination with standard doses of oral or IV busulfan, thus reducing the
toxicity previously observed with cyclophosphamide/ busulfan regimens.
The goal of this clinical research study is to learn if giving 1 unit of expanded cord blood
combined with 1 unit of non-expanded cord blood to a patient with leukemia or lymphoma can
help the transplant to "take" faster. The safety of this combination will also be studied.
Chemotherapy and/or 1 dose of radiation therapy will also be given before the transplant.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.